<DOC>
	<DOCNO>NCT00712881</DOCNO>
	<brief_summary>Evaluate efficacy safety treatment MYOCET® combination Cyclophosphamide Trastuzumab , 4 cycle , follow Docetaxel plus Trastuzumab , 4 cycle , woman stage II III breast cancer whose tumour overexpresses HER2 gene .</brief_summary>
	<brief_title>Combination Therapy With MYOCET® ( Doxorubicin HCL Liposome Injection ) Patients With HER2-Positive Breast Cancer</brief_title>
	<detailed_description>A multicentre , open-label , randomize , Phase 2 study evaluate efficacy safety treatment MYOCET® combination cyclophosphamide trastuzumab versus free doxorubicin combination cyclophosphamide , follow docetaxel trastuzumab , woman stage II III breast cancer whose tumour overexpresses HER2 gene .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Main Treatmentnaive patient stage II III invasive breast cancer ( prove histologically/cytologically ) test show overexpressing human epidermal growth factor receptor 2 ( HER2 ) . Patients least one bidimensionally measurable lesion accord WHO criterion . The patient Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . The patient LVEF least 55 % assess multiplegated acquisition ( MUGA ) scan ( prefer ) echocardiography . The patient hematology serum chemistry laboratory test result within specific protocoldefined range . Women childbearing potential must use medically accept method contraception must agree continue use method duration treatment period 6 month last administration study drug . Main The patient : Has receive previous cancer therapy breast cancer . Has history CHF , angina pectoris , myocardial infarction . Has uncontrolled hypertension . Has infection , peptic ulcer , unstable diabetes mellitus . Has treat live virus vaccine within 8 week first administration study drug . Has impair hepatic renal function . Is pregnant lactate woman . ( Any woman become pregnant study withdrawn study . ) Has use investigational drug within one month screen visit . Has know hypersensitivity study drug active ingredient . Has inflammatory breast cancer . Has malignancy within five year ( except adequately treat carcinoma situ cervix basal squamous cell skin cancer ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>